All eyes are on the European Parliament and the Council as they review a proposal by the European Commission for a new directive relating to the transparency of the measures that national authorities adopt to regulate the pricing and reimbursement of medicinal products.
This article was published in the July 2012 issue of Scrip Regulatory Affairs.
